Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Lipella Pharmaceuticals (Nasdaq: LIPO) announced a 1-for-8 reverse stock split effective November 7, 2024, with split-adjusted trading beginning November 8, 2024. The measure aims to comply with Nasdaq Capital Market's minimum bid price requirement. The split was approved by stockholders on September 10, 2024. The company's authorized shares will remain at 200,000,000, with a par value of $0.0001 per share. Nevada Agency and Transfer Company will serve as the exchange agent, with stockholders receiving transition information directly.
Lipella Pharmaceuticals (Nasdaq: LIPO) ha annunciato un raggruppamento azionario 1 per 8 che entrerà in vigore il 7 novembre 2024, con la negoziazione regolata a partire dall'8 novembre 2024. Questa misura mira a rispettare il requisito del prezzo minimo di offerta del Nasdaq Capital Market. Il raggruppamento è stato approvato dagli azionisti il 10 settembre 2024. Il numero autorizzato di azioni rimarrà a 200.000.000, con un valore nominale di $0.0001 per azione. Nevada Agency and Transfer Company agirà come agente di cambio, con gli azionisti che riceveranno informazioni sul passaggio direttamente.
Lipella Pharmaceuticals (Nasdaq: LIPO) anunció un split inverso de acciones 1 por 8 que entrará en vigor el 7 de noviembre de 2024, con la negociación ajustada comenzando el 8 de noviembre de 2024. Esta medida tiene como objetivo cumplir con el requisito de precio mínimo de oferta del Nasdaq Capital Market. El split fue aprobado por los accionistas el 10 de septiembre de 2024. Las acciones autorizadas de la compañía permanecerán en 200,000,000, con un valor nominal de $0.0001 por acción. Nevada Agency and Transfer Company actuará como agente de cambio, y los accionistas recibirán información de transición directamente.
리펠라 제약회사 (Nasdaq: LIPO)는 1대 8 비율의 주식 분할을 발표했으며, 이는 2024년 11월 7일부터 시행되며, 2024년 11월 8일부터 거래가 조정됩니다. 이 조치는 Nasdaq 자본 시장의 최소 매도 가격 요구사항을 준수하기 위한 것입니다. 이 분할은 2024년 9월 10일 주주들의 승인을 받았습니다. 회사의 승인 주식 수는 200,000,000주로 유지되며, 주당 액면가는 $0.0001입니다. 네바다 에이전시 및 트랜스퍼 컴퍼니가 교환 대리인으로 활동하며, 주주들은 직접 전환 정보를 받을 것입니다.
Lipella Pharmaceuticals (Nasdaq: LIPO) a annoncé un rachat d'actions inversé 1 pour 8 qui prendra effet le 7 novembre 2024, avec un début de négociation ajusté le 8 novembre 2024. Cette mesure vise à respecter l'exigence de prix minimum d'offre du Nasdaq Capital Market. Le rachat a été approuvé par les actionnaires le 10 septembre 2024. Le nombre d'actions autorisées de l'entreprise restera à 200 000 000, avec une valeur nominale de 0,0001 $ par action. Nevada Agency and Transfer Company agira en tant qu'agent de change, les actionnaires recevant des informations de transition directement.
Lipella Pharmaceuticals (Nasdaq: LIPO) hat einen 1-zu-8-Rücksplit bekannt gegeben, der am 7. November 2024 in Kraft tritt, wobei der Handel mit angepassten Anteilen am 8. November 2024 beginnt. Diese Maßnahme zielt darauf ab, die Mindestgebotsanforderung des Nasdaq Capital Markets zu erfüllen. Der Split wurde am 10. September 2024 von den Aktionären genehmigt. Die autorisierten Aktien des Unternehmens bleiben bei 200.000.000, mit einem Nennwert von 0,0001 USD pro Aktie. Nevada Agency and Transfer Company wird als Austauschagent fungieren, wobei die Aktionäre direkt Übergangsinformationen erhalten.
- None.
- Implementation of reverse stock split indicates struggle to maintain Nasdaq listing requirements
- Potential investor concern over stock price performance necessitating the reverse split
- Risk of shareholder value dilution through stock consolidation
Insights
This reverse stock split represents a significant restructuring move aimed at maintaining Nasdaq listing compliance. With a tiny market cap of
PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of incorporation with the Secretary of State of the State of Delaware. The Company expects that its common stock will begin trading on a split-adjusted basis when the market opens on November 8, 2024, under its current trading symbol “LIPO.” Following the reverse stock split, the CUSIP number for the Company’s common stock will be updated to 53630L209.
The reverse stock split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Stockholders approved the reverse stock split at the Company’s Annual Meeting of Stockholders held on September 10, 2024, with the Board of Directors subsequently approving the 1-for-8 ratio.
The reverse stock split will not impact the number of authorized shares of common stock of the Company, which will remain at 200,000,000, nor will it affect the par value of common stock, which remains
The 1-for-8 reverse stock split will convert eight shares of the Company’s common stock into one new share of common stock.
The Company’s transfer agent, Nevada Agency and Transfer Company, will act as the exchange agent for the reverse stock split. Stockholders of record will receive information from Nevada Agency and Transfer Company regarding the transition. Stockholders who hold shares through in book-entry form or through a broker or other nominee will have their positions adjusted automatically to reflect the reverse stock split and will not need to take any action. Nevada Agency and Transfer Company can be reached at (775) 322-0626 to address questions regarding the exchange process.
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in December 2022. Learn more at lipella.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, which are not historical facts, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements, including statements herein on the effective date of the reverse stock split and the date that trading of our common stock will begin on a split-adjusted basis, are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties including, but not limited to, our ability to regain compliance with The Nasdaq Stock Market LLC (“Nasdaq”) listing standards, including the minimum bid price requirement, our ability to take other actions that may be required for our continued listing on Nasdaq, our current liquidity position and the need to obtain additional financing to support ongoing operations, and other risks as more fully described in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.
CONTACT
Jeff Ramson
PCG Advisory
jramson@pcgadvisory.com
646-863-6893
FAQ
When will Lipella Pharmaceuticals (LIPO) reverse stock split take effect?
What is the ratio of Lipella Pharmaceuticals (LIPO) reverse stock split?
Why is Lipella Pharmaceuticals (LIPO) implementing a reverse stock split?